MG-K10 is expected to become the world’s first long-acting anti-IL-4Rαmonoclonal antibody with a four-week dosing frequency to be launched on the market, and has the potential to become the Best-in-Class Its Phase III clinical study in adults with moderate-to-severe AD in China has achieved positive results, meeting the primary endpoint, and at 52 weeks of treatment with MG-K10, 76.6% of patients achieved an IGA score of 0/1, with an improvement of ≥2 points from baseline; 94.3% and 79.1% of patients achieved EASI 75 and EASI 90, respectively. The overall safety profile was favorable. The incidence of common adverse reactions (conjunctivitis, injection site reactions, etc.) of drugs with the same target is relatively low for MG-K10. The Product will further enrich Dermavon’s portfolio in the AD field. It will generate synergy with ruxolitinib cream(for mild to moderate AD), the oral small molecule TYK2 inhibitor CMS-D001 (for moderate to severe AD), and the […]
Learn More
On October 28, the “2025 Shenzhen Top 500 Enterprises” list, released by the Shenzhen Enterprise Confederation and Shenzhen Entrepreneur Association, was officially announced. Shenzhen Kangzhe Pharmaceutical Co., Ltd. (“Shenzhen Kangzhe”), a wholly-owned subsidiary of China Medical System Holdings Limited (“CMS” or “the Group”), was once again made the list with honor, ranking at 166th, by virtue of its steady operational performance, outstanding innovation capabilities, and sustained social contributions. Additionally, Shenzhen Kangzhe was also included in the “2025 Top 100 Most Efficient Enterprises of the Shenzhen Top 500” and the “2025 Top 100 Enterprises with the Highest Social Contributions of the Shenzhen Top 500”. The five consecutive listings of Shenzhen Kangzhe not only reflect the high recognition of its remarkable operational resilience and vibrant innovation vitality in the complex market environment, but also demonstrate the Group’s continuous improvement in scale efficiency and the accelerated release of its quality growth […]
Learn More
Ranibizumab Injection (“Lucentis®”) is the first anti-VEGF drug approved for ophthalmic use in China. It is also currently the anti-VEGF drug in China that covers the widest age range and has the most indications[1], with its efficacy and safety verified by more than 200 clinical studies Brolucizumab Injection (“Beovu®”) is the current anti-VEGF drug with the smallest molecular weight (only 26 kDa). The producthas been approved for DME and recommended as a first-line therapy by the authoritative guideline[2]. In the global Phase 3 KESTREL and KITE Studies, Beovu® met all primary efficacy endpoints and the visual benefit persisted until Week 100, while showing superiority in fluid resolution. The median number of injections of Beovu® in the first year (7 times) was lower than that of aflibercept (9 times), while its overall safety profile was comparable to the latter Both collaborative products have been approved for marketing in China, and they will generate strong synergies with CMS Vision’s […]
Learn MoreThe news on this page is intended to share cutting-edge medical information and is for academic reference only by medical and health professionals, not for advertising purposes. CMS does not recommend any drugs, medical devices and/or indications. The news information on this page is for reference only. Please follow the advice or guidance of your doctor or other healthcare professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. If you have understood and confirmed the above content, please click OK to enter.
